Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jazz Pharmaceuticals is conducting a Phase 3 study titled ‘A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician’s Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer.’ The study aims to evaluate the efficacy and safety of zanidatamab combined with chemotherapy compared to trastuzumab combined with chemotherapy in patients with metastatic HER2-positive breast cancer who have not responded to or cannot tolerate previous treatments.
The study tests two main interventions: zanidatamab and trastuzumab, both administered with chemotherapy. Zanidatamab is being tested for its potential to offer a new treatment option for patients with advanced HER2-positive breast cancer.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. Participants are allocated to receive either zanidatamab or trastuzumab, each combined with a physician’s choice of chemotherapy.
The study began on August 13, 2024, with a primary completion date yet to be announced. The last update was submitted on July 1, 2025, indicating ongoing recruitment and data collection.
This study could significantly impact Jazz Pharmaceuticals’ market position, especially if zanidatamab proves more effective than current treatments. Positive results could boost investor confidence and stock performance, while also influencing the competitive landscape in the HER2-positive breast cancer treatment market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.